BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Cardiac Science Inc. (CSCX) Enhances R&D; Pursues Greater Speed to Market With 3-year Offshore Design Agreement Patni to Provide Design and Engineering Support for New Technology Initiatives


9/14/2009 11:16:19 AM

BOTHELL, Wash., Sept. 14 /PRNewswire-FirstCall/ -- Cardiac Science Corporation , a global leader in automated external defibrillator (AED) and diagnostic cardiac monitoring devices, announced a three-year agreement with Patni Computer Systems under which Patni will establish a dedicated design center in India and will expand Cardiac Science's existing in-house design and development capability.

"One of our strategies is to increase the volume and frequency of new product introductions, particularly in Cardiac Monitoring. We have great brands and distribution channels we want to better leverage," said Dave Marver, Cardiac Science president and chief executive officer. "This agreement provides us the resources and flexibility to pursue multiple new product development initiatives simultaneously."

"Our mandate is to increase the speed-to-market while keeping costs in check," said Bob Odell, senior vice president of strategy, design, and operations for Cardiac Science. "This agreement, like the Syncroness relationship we announced earlier this year, dramatically increases our engineering capacity and allows internal team members to focus on changing market dynamics, new customer solutions, and new revenue opportunities."

Cardiac Science develops, manufactures, and markets a family of advanced diagnostic and therapeutic cardiology devices and systems, including automated external defibrillators (AED), electrocardiograph devices (ECG/EKG), cardiac stress treadmill and systems, Holter monitoring systems, hospital defibrillators, cardiac rehabilitation telemetry systems, and cardiology data management systems (informatics) that connect with hospital information (HIS), electronic medical record (EMR), and other information systems. The company sells a variety of related products and consumables and provides a portfolio of training, maintenance, and support services. Cardiac Science, the successor to the cardiac businesses that established the trusted Burdick(R), HeartCentrix(R), Powerheart(R), and Quinton(R) brands, is headquartered in Bothell, Washington. With customers in more than 100 countries worldwide, the company has operations in North America, Europe, and Asia. For information, call 425.402.2000 or visit http://www.cardiacscience.com.

About Patni Computer Systems

Forward-Looking Statements


This press release contains forward-looking statements. The words "believe," "expect," "intend," "anticipate," variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. Forward-looking statements in this press release include, but are not limited to, those relating to Cardiac Science Corporation's expectations regarding cost savings or improved research and development capabilities and the resulting impact on operating results. These are forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause or contribute to such varying results and other risks are more fully described in Cardiac Science Corporation's Annual Report on Form 10-K for the year ended December 31, 2008, as updated by subsequent quarterly reports on Form 10-Q. Cardiac Science Corporation undertakes no duty or obligation to update the information provided herein.

LOGO: http://www.cardiacscience.com/images/main_logo.gif

SOURCE Cardiac Science Corporation



CONTACT: Mike Matysik, Senior Vice President and CFO of Cardiac Science
Corporation, +1-425-402-2009; or Investors, Matt Clawson of Allen & Caron,
+1-949-474-4300, matt@allencaron.com; or Media, Christopher Gale of EVC
Group Inc., +1-646-201-5431, +1-203-570-4681, cgale@evcgroup.com, both for
Cardiac Science Corporation

Web site: http://www.cardiacscience.com/



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES